Case VectorY’s VTx-002
Advanced therapies VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2 27 July 2026 Annogen is proud to announce a major milestone for our partner, VectorY Therapeutics, following the U.S. FDA’s IND clearance to proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002. This first-in-class vectorized antibody targets pathological TDP-43, the protein driving up […]
Case Orchard
Advanced therapies Annogen Announces Research Collaboration with Orchard Therapeutics for the Development of CNS-cell Specific Promoters 27 July 2026 Annogen, a company with expertise in bespoke promoter design and gene expression engineering, today announced a research collaboration with Orchard Therapeutics, a global gene therapy leader, for the identification of immune cell-specific human promoters for use […]
Annogen announces successful identification of cell-specific promoters for Orchard Therapeutics’ preclinical gene therapy programs
Orchard Therapeutics and Annogen announced the successful identification of novel human promoters for use in Orchard’s pre-clinical hematopoietic stem cell (HSC) gene therapy programs.
Annogen – KeyGene collaboration demonstrates efficacy of the SuRE™ platform to identify gain-of-function in new variants of crops
A collaboration started in 2021 has led to the identification of sequence variants that upregulate important traits in plants, demonstrating the efficacy of SuRE™-based variant screening in crops.
